PharmaCyte Biotech, Inc. filed Amendment No. 2 to its Schedule 13D with the SEC on November 20, 2026, disclosing a series of transactions involving Q/C Technologies, Inc. common stock and preferred securities that raised its beneficial ownership to 49.99% of the issuer's outstanding common stock.
Key Highlights
- Warrant exchange completed: PharmaCyte Biotech exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026, with shares delivered November 18, 2026.
- Exchange price basis: According to the filing, the number of exchange shares equals the Black-Scholes value of the exchange warrants divided by $0.3101 per share, the closing price on the last trading day before the agreement was signed.
- Beneficial ownership at 49.99%: PharmaCyte Biotech reported aggregate beneficial ownership of 8,446,093 shares, representing 49.99% of the class, including 5,152,000 shares of common stock held directly and 3,294,093 shares acquirable via warrants and preferred stock conversions.
- Series H maturity extended: Pursuant to the Consent Agreement, PharmaCyte consented to an amendment extending the maturity date of the Series H Convertible Preferred Stock from March 2, 2027 to September 2, 2027, for no additional consideration.
- Omnibus Amendment signed: On November 20, 2026, PharmaCyte and Q/C Technologies entered into an Omnibus Amendment Agreement amending the Series G and Series H Certificates of Designations and the Series G Long-Term Warrants, including a 49.99% beneficial ownership limitation cap on conversions and exercises.
- Dividend share acquisitions: The filing also disclosed that PharmaCyte received 127,296 shares on July 31, 2026, and 42,432 shares on October 1, 2026, in connection with Series G dividend declarations, both at a valuation of $3.3717 per share, with no additional cash paid.
PharmaCyte Biotech Restructures Q/C Technologies Holdings Through Warrant Exchange and Omnibus Amendment
According to the Schedule 13D Amendment No. 2 filed on November 20, 2026, PharmaCyte Biotech, Inc. executed a Consent and Warrant Exchange Agreement with Q/C Technologies, Inc. (NASDAQ:QCLS) on November 15, 2026. Under that agreement, the reporting person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 newly issued shares of common stock. The filing states that no additional cash was paid for these shares, and the exchange shares were delivered on November 18, 2026. The share count was calculated by dividing the Black-Scholes value of the warrants by $0.3101, described as the closing price of the common stock on the last trading day before signing.
As a result of these and earlier transactions, the filing reports PharmaCyte's aggregate beneficial ownership at 8,446,093 shares, representing 49.99% of the class. That percentage was calculated using a denominator comprising 8,619,201 shares outstanding as of November 13, 2026 (as reported in the issuer's Form 10-Q filed November 16, 2026), plus 4,982,272 shares issued under the Consent Agreement, plus 3,294,093 shares potentially acquirable through warrants and preferred stock conversions. PharmaCyte reported sole voting and dispositive power over all 8,446,093 shares, with no shared voting or dispositive power.
The filing also describes the Omnibus Amendment Agreement entered into on November 20, 2026, under which the parties agreed to amend the Series G and Series H Certificates of Designations and the terms of the Series G Long-Term Warrants. The filing states that the amended beneficial ownership limitation provisions prohibit PharmaCyte from converting preferred shares or exercising warrants to the extent doing so would cause it to beneficially own more than 49.99% of the outstanding common stock. The filing identifies PharmaCyte as the holder of at least a majority of the outstanding shares of each of the Series G and Series H Preferred Stock, constituting the "Required Holders" as defined in the applicable Certificate of Designations.
What Was Disclosed
PharmaCyte Biotech, Inc. filed Amendment No. 2 to its Schedule 13D disclosing the exchange of 851,304 warrants for 4,982,272 common shares, a Series H maturity extension, and an Omnibus Amendment imposing a 49.99% beneficial ownership cap on future conversions and exercises.




Please wait processing your request...